image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Additional proxy soliciting materials - definitive

DEFA14A View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

An amendment to the SC 13G filing

SC 13G/A View HTML

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

Data provided by Kaleidoscope.